Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations

Neoplasia

Volumn 10, Issue 1, 2008, Pages 1-7

  Junker, Kerstin ^a   Van Oers, Johanna M M ^b   Zwarthoff, Ellen C ^b   Kania, Ines ^a   Schubert, Joerg ^a   Hartmann, Arndt ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; TUMOR MARKER;

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER RISK; CANCER STAGING; CHROMOSOME ABERRATION; CHROMOSOME MICRODISSECTION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ISOLATION; GENE FREQUENCY; GENE MUTATION; GENETIC STABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 38649119486     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07178     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108.
2. Naski MC, Wang Q, Xu J, and Ornitz DM (1996). Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13, 233-237.
3. Wilcox WR, Tavormina PL, Krakow D, Kitoh H, Lachman RS, Wasmuth JJ, Thompson LM, and Rimoin DL (1998). Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. Am J Med Genet 78, 274-281.
4. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, and Radvanyi F (1999). Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23, 18-20.
5. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, and Zwarthoff EC (2001). The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61, 1265-1268.
6. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, et al. (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158, 1955-1959.
7. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, Tardon A, Carrato A, Serra C, Malats N, and Real FX (2006). Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24, 3664-3671.
8. Wu XR (2005). Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5, 713-725.
9. Spruck CHIII, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, et al. (1994). Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54, 784-788.
10. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, and Knuechel R (2002). Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62, 809-818.
11. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, and Zwarthoff EC (2005). A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 11, 7743-7748.
12. Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA, and Tunnacliffe A (1992). Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics 13, 718-725.
13. Chudoba IHT, Senger G, Claussen U, and Haas OA (1997). Comparative genomic hybridization using DOP-PCR amplified DNA from a small number of nuclei. Cs Pediatr 52, 519-521.
14. Mitra AP, Datar RH, and Cote RJ (2005). Molecular staging of bladder cancer. BJU Int 96, 7-12.
15. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, and Lerner SP (2004). p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22, 1014-1024.
16. Schoenberg M (2001). Biomarkers for transitional cell carcinoma-con. Urology 57, 849-851.
17. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boeve ER, Jobsis AC, and Zwarthoff EC (2003). Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21, 1912-1921.
18. Kram A, Li L, Zhang RD, Yoon DS, Ro JY, Johnston D, Grossman HB, Scherer S, and Czerniak B (2001). Mapping and genome sequence analysis of chromosome 5 regions involved in bladder cancer progression. Lab Invest 81, 1039-1048.
19. von Knobloch R, Bugert P, Jauch A, Kalble T, and Kovacs G (2000). Allelic changes at multiple regions of chromosome 5 are associated with progression of urinary bladder cancer. J Pathol 190, 163-168.
20. Tomovska S, Richter J, Suess K, Wagner U, Rozenblum E, Gasser TC, Moch H, Mihatsch MJ, Sauter G, and Schraml P (2001). Molecular cytogenetic alterations associated with rapid tumor cell proliferation in advanced urinary bladder cancer. Int J Oncol 18, 1239-1244.
21. Simon R, Burger H, Semjonow A, Hertle L, Terpe HJ, and Bocker W (2000). Patterns of chromosomal imbalances in muscle invasive bladder cancer [in process citation]. Int J Oncol 17, 1025-1029.
22. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H, Mihatsch MJ, and Sauter G (1998). Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 153, 1615-1621.
23. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, et al. (2004). Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 84, 465-478.
24. Prat E, Bernues M, Caballin MR, Egozcue J, Gelabert A, and Miro R (2001). Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology 57, 986-992.
25. Toncheva D and Zaharieva B (2005). Coexistence of copy number changes of different genes (INK4A, erbB-1, erbB-2, CMYC, CCND1 and ZNF217) in urothelial tumors. Tumour Biol 26, 88-93.
26. Zaharieva BM, Simon R, Diener PA, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Hering F, et al. (2003). High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 201, 603-608.
27. Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, Moch H, Mihatsch MJ, and Sauter G (1997). Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57, 2860-2864.
28. van Oers JM, Adam C, Denzinger S, Stoehr R, Bertz S, Zaak D, Stief C, Hofstaedter F, Zwarthoff EC, van der Kwast TH, et al. (2006). Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 119, 1212-1215.
29. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, et al. (2003). FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63, 8108-8112.
30. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, and Zwarthoff EC (2004). FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64, 1911-1914.
31. Dyrskjot L, Zieger K, Kruhoffer M, Thykjaer T, Jensen JL, Primdahl H, Aziz N, Marcussen N, Moller K, and Orntoft TF (2005). A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 11, 4029-4036.
32. Wu Z, Siadaty MS, Riddick G, Frierson HFJr, Lee JK, Golden W, Knuutila S, Hampton GM, El-Rifai W, and Theodorescu D (2006). A novel method for gene expression mapping of metastatic competence in human bladder cancer. Neoplasia 8, 181-189.
33. Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA, Tibshirani R, Maitra A, and Pollack JR (2005). Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 7, 556-562.